Relationship between maternal ABO blood groups and pregnancy outcomes: a retrospective cohort study in Dongguan, China

Jiang, Bi; Zhang, Xinjian; Wei, Sisi; He, Weichao

doi:10.1080/01443615.2023.2243508

Cited by 2 publications

(1 citation statement)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They found that ABO gene mutations was significantly associated with individual thrombotic risk [6]. Several studies observed the associations of ABO blood group system with pregnancy related outcomes, including stillbirth [7] and obstetrical hemorrhage risk [8]. Additionally, pregnant women with type O blood had a lower risk of cardiovascular disease comparing to those with type A, type B and type AB [9].…”

Section: Introductionmentioning

confidence: 99%

The effect of protein levels of ABO on pregnancy related outcomes: a Mendelian randomization study

Sun,

Zheng,

Wang

et al. 2023

Preprint

View full text Add to dashboard Cite

Protein level of Histo-Blood Group ABO System Transferase (ABO) has been reported to be associated with cardiometabolic diseases. But its effect on pregnancy related outcomes was still unclear. Here we conducted a two-sample Mendelian randomization study to ascertain the putative causal roles of protein levels of ABO in pregnancy related outcomes. Cis-acting protein quantitative trait loci (pQTLs) robustly associated with protein level of ABO (P<5x10-8) were used as instruments to proxy the ABO level (N=35,559, data from deCODE), with two additional pQTL datasets from Fenland (N=10,708) and INTERVAL (N=3,301) used as validation exposures. Ten pregnancy related diseases and complications were selected as outcomes. We observed that a higher protein level of ABO showed a putative causal effect on venous complications and haemorrhoids in pregnancy (OR=1.207, 95%CI=1.107-1.316, colocalization probability=91.3%), which was validated by using pQTLs from Fenland and INTERVAL. The Mendelian randomization results further showed effects of the ABO protein on gestational hypertension (OR=0.974, 95%CI=0.953-0.995), despite insignificance after multiple testing correction and little colocalization evidence. Sensitivity analyses, including proteome-wide Mendelian randomization of the cis-acting ABO pQTLs, showed little evidence of horizontal pleiotropy. Correctively, our study prioritised ABO as a putative causal protein for venous complications and haemorrhoids in pregnancy. Future epidemiology and clinical studies are needed to investigate whether ABO can be considered as a drug target to prevent adverse pregnancy outcomes.

show abstract